ClinicalTrials.gg
CompletedNCT03431974Updated Apr 14, 2023Results posted

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

A Phase 2 interventional study of LD-Aminopterin oral capsule and Placebo oral capsule in Psoriasis, sponsored by Syntrix Biosystems, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-14.

Sponsored by Syntrix Biosystems, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
568th of 675
19 · median 77
Started
2018
with 48 others
Phase 2
200 of 766
5 open now
Registered
480th of 766
by date

Among the 766 studies in Psoriasis with a site in United States, this one is the 568th largest by enrollment of the 675 interventional ones that give a count, is one of 49 that started in 2018, is one of 200 in phase 2, and was the 480th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 766 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if they are being treated with aminopterin or placebo.

Read the detailed description

A Phase 2, multi-center, randomized, double-blind, placebo-controlled study enrolling subjects with moderate-to-severe psoriasis to investigate the safety and efficacy of LD-aminopterin (AMT) (3 mg (six 0.5 mg tablets). Forty-six subjects will be randomized to one of two parallel treatment arms: LD-AMT (3 mg) or placebo, in a 1:1 ratio. The endpoint analysis will include efficacy and safety. Randomized subjects will initially enter a 14-week treatment phase, followed by a 6-week post-treatment phase.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Anti-folate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 18 years of age or older.
  2. Have a diagnosis of moderate-to-severe psoriasis for at least 6 months confirmed by a dermatologist, defined here as plaque-type psoriasis affecting a body surface area of >10% and a PASI of >10.
  3. Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study.
  4. Ability to understand and sign written .
  5. Heterosexually active men and women of must use two methods of during the study (20 weeks) and for 90 days after study completion. The two methods of birth control may be used simultaneously in the same subject or simultaneously in both partners. The two birth control methods can be (a) 2 barrier methods or (b) a barrier method plus a hormonal method to prevent pregnancy.

    Barrier methods include: condom (female or male), copper intrauterine device, sponge, or spermicide.

    Hormonal Methods include: any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent, including oral, subcutaneous, intrauterine, or intramuscular agents.

  6. For pre-menopausal women, a negative pregnancy test, obtained within 1 week prior to first study drug dose and at study visits Week 0, Week 6, Week10, Week 14, and Week 20. If at any visit during the Treatment Phase (see Appendix A) a positive pregnancy test is returned, the subject will be discontinued from any further study drug.
  7. Negative serology for 1 and 2 (HIV1/2), and .
  8. The following screening laboratory blood tests must have the following values, or not as determined by the PI and Medical Monitor: white blood cells (WBC) within normal limits (WNL); > lower limit of normal; count WNL; >10.0 g/dL; (AST) \< 2.5 x the .
  9. Adequate renal function: estimated by Cockcroft-Gault formula >60 ml/min

Exclusion criteria

Exclusion Criteria:

  1. Known history of hepatitis, infection, interstitial lung disease.
  2. Greater than moderate alcohol consumption on a regular basis (moderate consumption for females is 1 drink or 1 glass of wine a day; for males is 2 drinks or 2 glasses of wine a day) and unwilling, or unable, to control consumption during the study period.
  3. Prior use of aminopterin (AMT).
  4. Use of these biologic treatments in the time frames specified:

    • Within 9 months of first study drug dose: ustekinumab (Stelara).
    • Within 12 weeks of first study drug dose: any experimental therapy for psoriasis or rheumatoid arthritis.
    • Within 8 weeks of first study drug dose: infliximab (Remicade), adalimumab (Humira).
    • Within 4 weeks of first study drug dose: etanercept (Enbrel).
    • Other biologic therapies will have discontinuation periods determined by 5x their half-life.
  5. Within 90 days prior to Day 0 and at any time while on study, the use of MTX.
  6. Within 4 weeks prior to randomization and at any time while on study, use of phototherapy (e.g., ultraviolet B (UVB), narrow band UVB, Goeckerman regimen, Ingram regimen, PUVA), systemic medications (e.g. acitretin, mycophenolate mofetil, tacrolimus/FK506, cyclosporine A, azathioprine, 6-thioguanine, sulfasalazine, hydroxyurea, calcitriol, any systemic ), lithium, or any treatments that could affect psoriasis or sPGA evaluations. Subjects are eligible 4 weeks after the last dose of any of the aforementioned treatments was received.
  7. Within 2 weeks prior to randomization and at any time while on study, use of any topical medications or treatments that could affect psoriasis evaluations (e.g., , anthralin, vitamin D3/calcitriol and analogues such calcipotriene and tacalcitol, synthetic retinoids such as tazarotene, coal tar, and keratolytics such as salicylic acid, lactic acid and urea including those contained in over-the-counter medicated shampoos). Subjects are eligible 2 weeks after the last dose of any of the aforementioned treatments was received.

    Note: Over-the-counter topical steroids will be permitted for use limited to the face, axilla, and/or genitalia, as needed. These topical medications should not be used within approximately 24 hours prior to study visits Day 0 and Day 98. Over-the-counter shampoos for the treatment of psoriasis of the scalp are also permitted.

  8. Use of emollients on the morning of the first (Week 0) study visit.
  9. Within 2 weeks prior to Study Day 0, or on Study Day 0, or at any time during the study, use of any of the following medications that may result in drug/drug interactions with AMT: trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; pyrimethamine; tromethamine; salicylates; non-steroidal anti-inflammatory (NSAID) drugs including ibuprofen; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin).
  10. Known concurrent except basal or squamous cell skin carcinoma, or cervical carcinoma in situ.
  11. Concurrent participation in another clinical trial involving experimental treatment within 30 days of Study Day 0.
  12. Current and uncontrolled infection, cardiovascular, renal, pulmonary, hepatic or GI conditions that will interfere with the conduct of the trial or pose a morbid risk.
  13. Investigator's opinion that a concurrent disease or condition impairs the subject's ability to complete the trial: includes psychological, familial, sociological, geographical or medical conditions.
  14. Breast-feeding.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    LD-Aminopterin oral capsule

    LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).

    Drug: LD-Aminopterin oral capsule

  • Placebo comparator
    Placebo oral capsule

    Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).

    Drug: Placebo oral capsule

Interventions

  • DrugLD-Aminopterin oral capsule

    anti-folate treatment

    Also known as: racemic 4-Aminopteroylglutamic acid, racemic 4-Aminofolic acid

  • DrugPlacebo oral capsule

    Microcrystalline filled capsule to mimic capsule containing aminopterin tablets

    Also known as: Placebo (for aminopterin)

06

What researchers measure

Primary outcomes

  1. Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy)

    As follows: 1. Area of Involvement. Determine a score, from 0 to 6, for each body section (head, trunk, upper limbs, lower limbs) based on the percent of psoriasis skin involvement: 0=0%, 1=\<10%, 2=10% to \<30%, 3=30% to \<50%, 4=50% to \<70%, 5=70% to \<90%, 6=90% to 100%. 2. Severity of Involvement. Determine a score, from 0 to 4, for each body section (head, trunk, upper limbs, lower limbs), for the psoriatic skin severity of each of erythema, thickness, and scaling: 0=none, 1=slight, 2=moderate, 3=severe, 4=very severe. For each body section the three severity scores are summed. 3. For each body section the product of the Area and Severity is determined. 4. For each body section the product of line 3 is multiplied by an Area Factor (head=0.1, trunk=0.3, upper limbs=0.2, lower limbs=0.4). 5. A PASI score is determined by summing the 4 body section products (line 4). The highest possible score=72; the lowest possible score=0. The higher the scores, the worse the psoriasis.

    Time frame: 98 days.

  2. Success (Score of 0 or 1) in Static Physician Global Assessment (sPGA) (Efficacy)

    As follows: 1. Induration. A score, from 0 to 5, based on: 0=No plaque elevation; 1= Minimal plaque elevation=0.25 mm; 2=Mild plaque elevation=0.5 mm; 3=Moderate plaque elevation=0.75 mm; 4=Marked plaque elevation=1.0 mm; 5=Severe plaque elevation\>1.25 mm. 2. Erythema. A score, from 0 to 5, based on: 0=No erythema, hyperpigmentation may be present; 1=Faint erythema; 2=Light red coloration; 3=Moderate red coloration; 4=Bright red coloration; 5=Dusky to deep red coloration. 3. Scaling. A score, from 0 to 5, based on: 0= No scaling; 1=Minimal; occasional fine scale on\<5% of the lesion; 2=Mild; fine scale predominates; 3=Moderate; coarse scale predominates; 4=Marked; thick, non-tenacious scale predominates; 5=Severe; very thick, tenacious scale predominates. 4. The sPGA: Induration, Erythema, and Scaling scores are rounded to the nearest whole number and averaged. 0=Cleared; 1=Minimal; 2=Mild; 3=Moderate; 4=Marked; 5=Severe. Higher score indicates worse psoriasis.

    Time frame: 98 days.

07

Results

Posted Apr 14, 2023

Participant flow

Participant flow — Overall Study
MilestoneLD-Aminopterin Oral CapsulePlacebo Oral Capsule
Started118
Completed86
Not completed32

Outcome measures

PrimarySubjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy)

As follows: 1. Area of Involvement. Determine a score, from 0 to 6, for each body section (head, trunk, upper limbs, lower limbs) based on the percent of psoriasis skin involvement: 0=0%, 1=\<10%, 2=10% to \<30%, 3=30% to \<50%, 4=50% to \<70%, 5=70% to \<90%, 6=90% to 100%. 2. Severity of Involvement. Determine a score, from 0 to 4, for each body section (head, trunk, upper limbs, lower limbs), for the psoriatic skin severity of each of erythema, thickness, and scaling: 0=none, 1=slight, 2=moderate, 3=severe, 4=very severe. For each body section the three severity scores are summed. 3. For each body section the product of the Area and Severity is determined. 4. For each body section the product of line 3 is multiplied by an Area Factor (head=0.1, trunk=0.3, upper limbs=0.2, lower limbs=0.4). 5. A PASI score is determined by summing the 4 body section products (line 4). The highest possible score=72; the lowest possible score=0. The higher the scores, the worse the psoriasis.

Time frame:
98 days.
Reported as:
Count of participants · Participants
Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy)
ParticipantsLD-Aminopterin Oral CapsulePlacebo Oral Capsule
Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy)31
Statistical analysis
  • LD-Aminopterin Oral Capsule vs Placebo Oral Capsule · Fisher Exact · p = 0.43
PrimarySuccess (Score of 0 or 1) in Static Physician Global Assessment (sPGA) (Efficacy)

As follows: 1. Induration. A score, from 0 to 5, based on: 0=No plaque elevation; 1= Minimal plaque elevation=0.25 mm; 2=Mild plaque elevation=0.5 mm; 3=Moderate plaque elevation=0.75 mm; 4=Marked plaque elevation=1.0 mm; 5=Severe plaque elevation\>1.25 mm. 2. Erythema. A score, from 0 to 5, based on: 0=No erythema, hyperpigmentation may be present; 1=Faint erythema; 2=Light red coloration; 3=Moderate red coloration; 4=Bright red coloration; 5=Dusky to deep red coloration. 3. Scaling. A score, from 0 to 5, based on: 0= No scaling; 1=Minimal; occasional fine scale on\<5% of the lesion; 2=Mild; fine scale predominates; 3=Moderate; coarse scale predominates; 4=Marked; thick, non-tenacious scale predominates; 5=Severe; very thick, tenacious scale predominates. 4. The sPGA: Induration, Erythema, and Scaling scores are rounded to the nearest whole number and averaged. 0=Cleared; 1=Minimal; 2=Mild; 3=Moderate; 4=Marked; 5=Severe. Higher score indicates worse psoriasis.

Time frame:
98 days.
Reported as:
Count of participants · Participants
Success (Score of 0 or 1) in Static Physician Global Assessment (sPGA) (Efficacy)
ParticipantsLD-Aminopterin Oral CapsulePlacebo Oral Capsule
Success (Score of 0 or 1) in Static Physician Global Assessment (sPGA) (Efficacy)11

Adverse events

Collected over 98 days will on treatment and 42 days afterward (140 days total). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LD-Aminopterin Oral Capsule0/11 (0%)1/11 (9.1%)5/11 (45.5%)
Placebo Oral Capsule0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent serious events
Most frequent serious events
EventLD-Aminopterin Oral CapsulePlacebo Oral Capsule
Allergic reactionImmune system disorders1/110/8
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLD-Aminopterin Oral CapsulePlacebo Oral Capsule
NauseaGastrointestinal disorders0/111/8
DiarrheaGastrointestinal disorders0/111/8
SinusitisInfections and infestations0/111/8
DizzinessNervous system disorders0/111/8
Back painMusculoskeletal and connective tissue disorders0/111/8
Peripheral swellingGeneral disorders0/111/8
Abdominal painGastrointestinal disorders1/110/8
Tooth painGastrointestinal disorders1/110/8
PharyngitisInfections and infestations1/110/8
HeadacheNervous system disorders1/110/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)LD-Aminopterin Oral CapsulePlacebo Oral CapsuleTotal
Mean50.0 ± 10.350.0 ± 13.150.0 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)LD-Aminopterin Oral CapsulePlacebo Oral CapsuleTotal
Female123
Male10616
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LD-Aminopterin Oral CapsulePlacebo Oral CapsuleTotal
Hispanic or Latino123
Not Hispanic or Latino10616
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LD-Aminopterin Oral CapsulePlacebo Oral CapsuleTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White11718
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)LD-Aminopterin Oral CapsulePlacebo Oral CapsuleTotal
United States11819
08

Study locations

3 sites
  • Spectrum Dermatology
    Scottsdale, Arizona 85258, United States
  • Dermatology Associates of Seattle
    Seattle, Washington 98101, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708. doi: 10.1124/jpet.112.195479. Epub 2012 May 31. PubMed 22653877 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jan 2021, 26 months.

Results were first posted in Apr 2023, 2 years 3 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 26 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 13, 2018
StartActual
Nov 1, 2018
Primary completionActual
Jan 11, 2021
CompletionActual
Jan 11, 2021
Results first posted
Apr 14, 2023
Last update
Apr 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03431974
Lead sponsor
Syntrix Biosystems, Inc.
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Nov 1, 2018
Primary completion
Jan 11, 2021
Completion
Jan 11, 2021
Results posted
Apr 14, 2023
Last update
Apr 14, 2023

Study contacts

Stuart Kahn, MD
study director · Syntrix Biosystems

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion